Company intelligence / Profile preview

Impacter

Ownership: Private
Development stage: Other

Overview

ImPact Biotech is conducting a pivotal Phase 3 trial ("ENLIGHTED" study) of Padeliporfin VTP in low-grade upper tract urothelial carcinoma. Interim analysis at 50% enrollment was presented at ASCO 2025, with topline results expected later in the year. Earlier-stage studies are ongoing or planned for high-grade UTUC, PDAC, and NSCLC. The platform has shown promising safety and efficacy profiles based on prior research in prostate cancer and early solid tumor studies.

Therapeutic areas: Oncology
Modalities: Small moleculeDrug-device combination therapyPhotodynamic therapy agent
Industry: Biotech

Partnerships

Longstanding collaborations with Weizmann Institute of Science (Israel)Memorial Sloan Kettering Cancer Center (US)

Beyond the preview

Go deeper on Impacter.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Impacter.

Explore the full profile